Besides Wall Street's top-and-bottom-line estimates for Pfizer (PFE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the ...

Over 100 major companies — including MicroStrategy, Coinbase, AMD, Pfizer, and Boeing — are set to report earnings today, July 31. From crypto and AI to healthcare and industrials, here's the full ...

For many investors, the main point of stock picking is to generate higher returns than the overall market. But in ...

Pfizer (NYSE: PFE) has been around for over 175 years, but it became a true household name during the COVID-19 pandemic as ...

Pfizer faces weak growth, sector headwinds, and pipeline uncertainty despite cost cuts and a 7% yield, weighing on sentiment.

Bristol Myers Squibb posted much better-than-expected second-quarter results on Wednesday on strong sales of its most ...

Pfizer should have different top-selling drugs in 2030 with a heavier focus on oncology. The drugmaker should be more ...

Pfizer Inc. (NYSE:PFE) is one of the most undervalued blue chip stocks to buy according to hedge funds. Analyst Tim Anderson from Bank of America Securities maintained a Hold rating on Pfizer Inc.

The American multinational biotech firm developed a form of santonin used to treat intestinal worms, which gained rapid ...

Disclosure: None. This article is originally published at Insider Monkey.

In the cutthroat pharmaceutical arena, Pfizer stands poised for a strategic pivot and a potential earnings bonanza in 2025.

On July 30, 2025, Pfizer (PFE) saw its shares drop by 2.02%, with a trading volume hitting $0.86 billion and ranking 118th in ...